IDT 3.75% 7.7¢ idt australia limited

6 months report - 4 weeks away?

  1. 5,856 Posts.
    lightbulb Created with Sketch. 513
    These were the highlights last year:


    Major highlights during the half year include:
     COVID-19 Treatments, Vaccines and Sovereign Manufacturing
    During the reporting period IDT continued to operate as an essential service throughout the Victorian
    lockdowns. The Company’s activities assisting the Federal Government in its initial COVID-19 response
    efforts announced in April 2020 were successfully completed in the half year ended 31 December 2020.
    In August 2020, IDT made a formal submission to the Federal Government’s COVID-19 Vaccine and
    Treatment Manufacture and Supply Chain Request For Information (RFI). IDT’s RFI submission put
    forward the Company’s current and potential facilities and capabilities in relation to the possible
    manufacture and supply of COVID-19 treatments and vaccines. IDT’s COVID-19 treatment
    manufacturing capabilities include our ability to manufacture Active Pharmaceutical Ingredients (APIs)
    as well as finished dosage forms. The Company’s sterile manufacturing suite was also showcased in
    IDT’s RFI submission as being potentially capable of producing COVID-19 vaccines. Discussions with
    various parties are continuing.
    Throughout the COVID-19 crisis, IDT has made several public submissions to the Australian
    Government to highlight the sovereign importance of increased local manufacturing of essential
    medicines. In December 2020, the Federal Government’s Joint Standing Committee “Inquiry into the
    implications of the COVID-19 pandemic for Australia’s foreign affairs, defence and trade”, released its
    final report. The Government’s report contained sixteen recommendations which included: The need to
    define which critical national systems are essential for Australia to function as a secure and prosperous
    first world nation, identifying those elements of the critical national systems with potential foreign supply
    chain dependencies and the use of Government procurement to build and sustain sovereign capacity
    2
    IDT AUSTRALIA LIMITED (ACN 006 522 970)
    and to develop plans to move from “at risk” supply chains for critical national systems to sovereign
    Australian suppliers.
    The Company’s efforts to build momentum for re-shoring the manufacturing of Australia’s essential
    medicines have also continued behind the scenes with workshops and industry groups. In late December
    2020, the final report from the Institute for Integrated Economic Research Australia (IIER) regarding
    Australia’s pharmaceutical supply chain resilience was released. The report highlighted Australia’s
    inadequacies and lack of resilience in its healthcare systems, and the need to move away from a “just
    in time” market philosophy where Australia now imports over 90% of its medicines.

    What news can we expect by end Feb.?
 
watchlist Created with Sketch. Add IDT (ASX) to my watchlist
(20min delay)
Last
7.7¢
Change
-0.003(3.75%)
Mkt cap ! $27.06M
Open High Low Value Volume
8.0¢ 8.0¢ 7.7¢ $3.456K 44.18K

Buyers (Bids)

No. Vol. Price($)
1 25886 7.7¢
 

Sellers (Offers)

Price($) Vol. No.
8.2¢ 14250 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
7.7¢
  Change
-0.003 ( 2.53 %)
Open High Low Volume
7.8¢ 7.8¢ 7.7¢ 34854
Last updated 15.59pm 28/03/2024 ?
IDT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.